Avicanna Inc (AVCN) - Net Assets
Based on the latest financial reports, Avicanna Inc (AVCN) has net assets worth CA$12.79 Million CAD (≈ $9.25 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$22.08 Million ≈ $15.97 Million USD) and total liabilities (CA$9.29 Million ≈ $6.72 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Avicanna Inc tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$12.79 Million |
| % of Total Assets | 57.93% |
| Annual Growth Rate | N/A |
| 5-Year Change | 64.83% |
| 10-Year Change | N/A |
| Growth Volatility | 1004.44 |
Avicanna Inc - Net Assets Trend (2016–2025)
This chart illustrates how Avicanna Inc's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Avicanna Inc to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Avicanna Inc (2016–2025)
The table below shows the annual net assets of Avicanna Inc from 2016 to 2025. For live valuation and market cap data, see Avicanna Inc (AVCN) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CA$11.39 Million ≈ $8.24 Million |
+16.88% |
| 2024-12-31 | CA$9.74 Million ≈ $7.05 Million |
+22.20% |
| 2023-12-31 | CA$7.97 Million ≈ $5.77 Million |
+130.50% |
| 2022-12-31 | CA$3.46 Million ≈ $2.50 Million |
-49.93% |
| 2021-12-31 | CA$6.91 Million ≈ $5.00 Million |
-50.34% |
| 2020-12-31 | CA$13.91 Million ≈ $10.06 Million |
-53.44% |
| 2019-12-31 | CA$29.88 Million ≈ $21.61 Million |
+13.25% |
| 2018-12-31 | CA$26.38 Million ≈ $19.08 Million |
+3036.45% |
| 2017-12-31 | CA$841.07K ≈ $608.42K |
+2925.98% |
| 2016-12-31 | CA$-29.76K ≈ $-21.53K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Avicanna Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10520675500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CA$88.26 Million | 3103.61% |
| Other Comprehensive Income | CA$19.82 Million | 697.13% |
| Total Equity | CA$2.84 Million | 100.00% |
Avicanna Inc Competitors by Market Cap
The table below lists competitors of Avicanna Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Finlay Minerals Ltd
V:FYL
|
$12.29 Million |
|
Regenbogen AG
F:RGB
|
$12.30 Million |
|
Walker River Resources Corp.
V:WRR
|
$12.31 Million |
|
Phio Pharmaceuticals Corp
NASDAQ:PHIO
|
$12.31 Million |
|
Birlik Mensucat Ticaret ve Sanayi Isletmesi AS
IS:BRMEN
|
$12.28 Million |
|
Jianzhi Education Technology Group Company Limited American Depositary Shares
NASDAQ:JZ
|
$12.28 Million |
|
Voyageur Pharmaceuticals Ltd
V:VM
|
$12.27 Million |
|
Big Rock Brewery Inc.
TO:BR
|
$12.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Avicanna Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,312,859 to 2,843,660, a change of 530,801 (22.9%).
- Net loss of 2,844,215 reduced equity.
- New share issuances of 1,000,000 increased equity.
- Other comprehensive income increased equity by 21,956,459.
- Other factors decreased equity by 19,581,443.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-2.84 Million | -100.02% |
| Share Issuances | CA$1.00 Million | +35.17% |
| Other Comprehensive Income | CA$21.96 Million | +772.12% |
| Other Changes | CA$-19.58 Million | -688.6% |
| Total Change | CA$- | 22.95% |
Book Value vs Market Value Analysis
This analysis compares Avicanna Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.45x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CA$0.00 | CA$0.14 | x |
| 2017-12-31 | CA$0.06 | CA$0.14 | x |
| 2018-12-31 | CA$1.17 | CA$0.14 | x |
| 2019-12-31 | CA$1.09 | CA$0.14 | x |
| 2020-12-31 | CA$0.20 | CA$0.14 | x |
| 2021-12-31 | CA$0.03 | CA$0.14 | x |
| 2022-12-31 | CA$-0.01 | CA$0.14 | x |
| 2023-12-31 | CA$0.00 | CA$0.14 | x |
| 2024-12-31 | CA$0.02 | CA$0.14 | x |
| 2025-12-31 | CA$0.02 | CA$0.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Avicanna Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -100.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -11.16%
- • Asset Turnover: 1.20x
- • Equity Multiplier: 7.47x
- Recent ROE (-100.02%) is above the historical average (-271.33%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-26.86K |
| 2017 | -309.08% | -9750.46% | 0.01x | 2.52x | CA$-2.68 Million |
| 2018 | -38.77% | -6017.58% | 0.00x | 1.54x | CA$-8.93 Million |
| 2019 | -99.22% | -13202.22% | 0.00x | 2.02x | CA$-24.45 Million |
| 2020 | -546.23% | -2093.12% | 0.05x | 5.01x | CA$-33.46 Million |
| 2021 | -1463.55% | -513.15% | 0.15x | 19.46x | CA$-16.89 Million |
| 2022 | 0.00% | -364.01% | 0.23x | 0.00x | CA$-14.70 Million |
| 2023 | 0.00% | -52.07% | 0.76x | 0.00x | CA$-8.73 Million |
| 2024 | -156.43% | -14.21% | 1.27x | 8.70x | CA$-3.85 Million |
| 2025 | -100.02% | -11.16% | 1.20x | 7.47x | CA$-3.13 Million |
Industry Comparison
This section compares Avicanna Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $792,378,634
- Average return on equity (ROE) among peers: -15.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Avicanna Inc (AVCN) | CA$12.79 Million | 0.00% | 0.73x | $12.28 Million |
| Aurora Cannabis Inc (ACB) | $1.69 Million | -10.52% | 0.00x | $171.89 Million |
| Amotiv Limited (AOV) | $795.11 Million | 0.54% | 0.21x | $576.83 Million |
| Aequus Pharmaceuticals Inc (AQS) | $-6.45 Million | 0.00% | 0.00x | $479.73K |
| Avant Brands Inc (AVNT) | $32.85 Million | -68.65% | 0.81x | $6.98 Million |
| Bausch Health Companies Inc (BHC) | $5.94 Billion | 40.44% | 5.31x | $1.87 Billion |
| CanadaBis Capital Inc (CANB) | $2.63 Million | 23.10% | 4.88x | $1.53 Million |
| Cannabist Company Holdings Inc (CBST) | $266.93 Million | -39.33% | 0.51x | $12.41 Million |
| Cipher Pharmaceuticals Inc (CPH) | $18.41 Million | -56.20% | 0.05x | $297.74 Million |
| Cardiol Therapeutics Inc Class A (CRDL) | $76.24 Million | -32.43% | 0.15x | $118.76 Million |
About Avicanna Inc
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios … Read more